ClinConnect ClinConnect Logo
Search / Trial NCT05214092

Cortical Contributions to FFR: Post-Op Outcomes

Launched by UNIVERSITY OF PITTSBURGH · Jan 27, 2022

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

The purpose of this study is to better understand the cortical contribution of the human temporal lobe to the generation and modulation of frequency-following responses (FFR).

The specific aims of this study is as follows:

1. To build a novel computational model of cortical feedforward mechanisms involved in FFRs.
2. To test model predictions of cortical removal in human participants who have undergone surgical resection of Heschl's gyrus lesions.

The hypothesis to be tested for the previously listed purposes and aims are as follows:

1. When cortical areas involved in generating and mod...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Individuals 13-25 years old
  • Undergoing medically necessary surgical resection of Heschl's gyrus lesion
  • Monolingual English speakers
  • Receptive and expressive language within normal limits
  • Normal or corrected-to-normal visual acuity
  • Normal hearing acuity in each ear (as determined during an audiometric assessment)
  • Nonverbal IQ within normal limits
  • No history of autism spectrum disorder or attention-deficit hyperactivity disorder
  • Exclusion Criteria:
  • Significant medical or neuropsychological impairment that would result in the patient being unable to participate in study activities
  • History of autism or ADHD

About University Of Pittsburgh

The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.

Locations

Pittsburgh, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Taylor Abel, MD

Principal Investigator

University of Pittsburgh

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials